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MaBACKGROUND Platelet inhibition after percutaneous coronary intervention (PCI) reduces the risk of myocardial
infarction (MI) but increases the risk of bleeding. MIs and bleeds during the index hospitalization for PCI are known to
negatively affect long-term outcomes. The impact of spontaneous bleeding occurring after discharge on long-term
mortality is unknown.
OBJECTIVES This study sought to examine, in a real-world cohort, the association between spontaneous major
bleeding or MI after PCI and long-term mortality.
METHODS We conducted a retrospective cohort study of patients$30 years of age who underwent a PCI between 1996
and 2008 in an integrated healthcare delivery system. We used extended Cox regression to examine the associations of
spontaneous bleeding and MI with all-cause mortality, after adjustment for time-updated demographics, comorbidities,
periprocedural events, and longitudinal medication exposure.
RESULTS Among 32,906 patients who had a PCI and survived the index hospitalization, 530 had bleeds and 991 had
MIs between 7 and 365 days post-discharge. There were 4,048 deaths over a mean follow-up of 4.42 years. The crude
annual death rate after a spontaneous bleed (9.5%) or MI (7.6%) was higher than among patients who experienced
neither event (2.6%). Bleeding was associated with an increased rate of death (adjusted hazard ratio [HR]: 1.61, 95%
conﬁdence interval [CI]: 1.30 to 2.00), similar to that after an MI (HR: 1.91; 95% CI: 1.62 to 2.25). The association of
bleeding with death remained signiﬁcant after additional adjustment for the longitudinal use of antiplatelet agents.
CONCLUSIONS Spontaneous bleeding after a PCI was independently associated with higher long-term mortality, and
conveyed a risk comparable to that of an MI during follow-up. This tradeoff between efﬁcacy and safety bolsters the
argument for personalizing antiplatelet therapy after PCI on the basis of the patient’s long-term risk of both thrombotic
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ABBR EV I A T I ON S
AND ACRONYMS
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HR = hazard ratio
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MI = myocardial infarction
PCI = percutaneous coronary
intervention
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1412(5,6). Procedural bleeding is associated with
increased mortality during the index hospi-
talization and in the ﬁrst year after discharge
(1,3,7–13). The effect, if any, of spontaneous
bleeds that occur after hospital discharge
(i.e., nonprocedural bleeds) on long-term
outcomes is unclear.SEE PAGE 1421The potential impact of spontaneous bleeding on
long-term outcomes is important to assess for 2 rea-
sons. First, although strategies to reduce periproce-
dural bleeding are receiving increasing attention
(e.g., use of radial access for PCI), no such systematic
efforts are in place to reduce bleeding that occurs
after hospital discharge. Second, if spontaneous
bleeding were indeed associated with higher late
mortality, it would motivate careful consideration of
the net clinical beneﬁt of new antiplatelet and
antithrombotic agents that reduce myocardial in-
farctions (MIs), but increase bleeding. This tradeoff
between efﬁcacy and safety may bolster the argument
for personalizing the choice and duration of anti-
platelet therapy after PCI on the basis of the patient’s
long-term risk of both thrombotic and bleeding
events.
To address this issue, we examined the association
between major spontaneous bleeding or MI and long-
term risk of death in a large, community-based cohort
of patients receiving PCI within usual care clinical
settings. We hypothesized that spontaneous bleeds in
the ﬁrst year after PCI would be associated with
increased all-cause mortality that is comparable to
the risk associated with a spontaneous MI.
METHODS
SOURCE POPULATION. The source population was
from Kaiser Permanente Northern California, a large
integrated healthcare delivery system with >3.3
million members in the San Francisco and greater Bay
Area. The health plan membership is representative
of the regional and statewide population, apart from
slightly lower representation at the extremes of
income and age.
STUDY POPULATION. We used health plan electronic
health records to identify all members 30 years of age
and older who received PCI between January 1, 1996,
and December 31, 2008. We excluded patients who
had incomplete demographic data, or <12 months of
continuous membership and pharmacy beneﬁt before
the index procedure. We also excluded patients who
died either during the index hospitalization or within7 days after discharge because the outcome of interest
was long-term mortality. All patients were followed
through December 31, 2008 (the latest date for which
complete mortality data were available at the time of
analysis), or until disenrollment from the health plan,
deﬁned as a continuous gap in membership of 90 days
or longer.
OUTCOME. The primary outcome was death from any
cause through December 31, 2008, which was identi-
ﬁed from a combination of health plan hospitalization
and administrative records, California state death
certiﬁcate ﬁles, and Social Security Administration
vital status ﬁles (14,15).
EXPOSURES OF INTEREST. We deﬁned spontaneous
bleeding or MI as events occurring between days 7
and 365 after discharge from the index hospitaliza-
tion. We treated events occurring during the initial
hospital stay for PCI or within the ﬁrst 7 days after
discharge as procedural events because of the limited
temporal resolution of available electronic data. On
the basis of previously validated methods (16–19), we
used International Classiﬁcation of Diseases-Ninth
Edition, codes to identify subsequent hospitalizations
for MI (deﬁned as a primary discharge diagnosis of
an acute MI) or bleeding (a primary or secondary
discharge diagnosis of intracranial bleeding, or a pri-
mary discharge diagnosis of extracranial bleeding).
This was on the basis of our previous work demon-
strating a low positive predictive value of codes for
extracranial bleeds in the secondary position (17). We
did not evaluate the use of blood transfusions
because procedure codes are not sufﬁciently accurate
to identify them in our data (20,21).
COVARIATES. We obtained demographic and clinical
data from health plan electronic health records and
other associated databases. We identiﬁed comorbid
conditions up to 4 years before the date of the index
procedure and throughout follow-up using previously
validated approaches from health plan hospitaliza-
tion, ambulatory, laboratory, and pharmacy data-
bases (22–24). We obtained a time-updated history of
heart failure, diabetes mellitus, hypertension, dysli-
pidemia, mitral or aortic valvular heart disease, pe-
ripheral arterial disease, stroke or transient ischemic
attack, dementia, systemic cancer, hypothyroidism,
and chronic lung disease. We also identiﬁed previ-
ous hospitalizations for bleeding. Because kidney
dysfunction and anemia are predictors of both major
bleeding and mortality, we extracted baseline and
longitudinal estimated glomerular ﬁltration rates and
hemoglobin concentrations from the health plan lab-
oratory database (25–27). From health plan pharmacy
FIGURE 1 Study Cohort Assembly
Patients undergoing PCI,
index hospitalization data available
January 1996 to December 2008
n = 33,393
Death During 
Index Hospitalization
n = 487
Patients who survived to discharge 
from index hospitalization 
n = 32,906
Predictors of Interest: Events occurring from 7 to 365 days 
after discharge from index hospitalization
Outcome of Interest
MI Only Bleeding Only Both MI 
and Bleeding
n = 39
0.1%
Neither MI
nor Bleeding
n = 31,424
95.5%
Death
n = 294
30.9%
Death
n = 143
29.1%
Death
n = 21
53.8%
Death
n = 3,590
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We used health plan electronic health records to identify all members aged 30 years
and older who received percutaneous coronary intervention (PCI) at a large, integrated
healthcare delivery system with more than 3.3 million enrollees in the San Francisco
Bay Area. This ﬁgure depicts mutually exclusive categories of predictor events.
MI ¼ myocardial infarction.
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1413records, we obtained data on the longitudinal use of
the following prescription medications: angiotensin-
converting enzyme inhibitors; angiotensin II recep-
tor blockers; beta-blockers; diuretic agents, digoxin;
statins, nonstatin lipid-lowering agents; nitrates;
calcium-channel blockers; diabetes medications; anti-
inﬂammatory drugs; warfarin; and antiplatelet agents
(clopidogrel and ticlopidine). We then applied vali-
dated algorithms to characterize longitudinal expo-
sure to these agents on the basis of information from
dispensed prescriptions and the timing of reﬁlls
(23,28). We could not reliably ascertain aspirin ther-
apy because the majority of aspirin use in our popu-
lation is over-the-counter and not captured in health
plan pharmacy-dispensing databases. However,
aspirin use among patients who have undergone a PCI
in our population is nearly universal (29).
STATISTICAL ANALYSIS. We compared baseline
characteristics using the Student t test or Wilcoxon
rank sum test for continuous variables and the chi-
square test for categorical variables. We used an
extended Cox regression model to evaluate the in-
dependent association of a spontaneous bleed or MI
with death, after adjustment for baseline and time-
updated confounders. The use of a time-updated
model allowed each patient to contribute unexposed
person-time (before a spontaneous bleed or MI) as
well as exposed person-time (e.g., after the sponta-
neous bleed or MI). Similarly, the time-updated
model allowed us to adjust for longitudinal changes
in potential confounders (e.g., development of dia-
betes or chronic kidney disease during follow-up).
Because few patients experienced both an MI and a
bleed during follow-up, a separate hazard ratio for
death was not estimated for this subgroup. We
repeated the analysis, stratiﬁed by whether the index
PCI was urgent/emergent (i.e., performed in the
setting of acute coronary syndrome) or elective.
Finally, because patients who bleed may discontinue
their antiplatelet therapy afterwards, we conducted a
mediation analysis that adjusted for antiplatelet
agent use and timing during follow-up to explore
whether doing so attenuated any observed associa-
tion between occurrences of bleeding or MI with
death. All analyses were performed using SAS statis-
tical software, version 9.1.3 (Cary, North Carolina).
A.G. and T.F. had direct access to the data, and all
authors take full responsibility for the integrity of the
study results.
The Kaiser Foundation Research Institute and
Stanford University Institutional Review Boards
approved the study. Due to the nature of the study,
waiver of informed consent was obtained.RESULTS
The study population consisted of 33,393 patients
who underwent PCI between 2002 and 2008
(Figure 1). Overall, 487 died during the index hospi-
talization or within 7 days after discharge and were
excluded from this analysis. Among the 32,906 pa-
tients discharged alive after PCI, 14% had a PCI for the
treatment of an acute coronary syndrome, while the
remainder had an elective PCI procedure. During a
mean 4.42 years of follow-up, 530 patients were
hospitalized for a spontaneous bleed (crude rate: 2.14
per 100 person-years; 95% conﬁdence interval [CI]:
1.98 to 2.31), which occurred at a median of 100
(interquartile range [IQR]: 40 to 209) days post-
TABLE 1 Baseline Clinical Characteristics
Entire Cohort
(N ¼ 32,906)
By Bleeding Status By MI Status
Spontaneous Bleed*
(n ¼ 530)
No Spontaneous Bleed
(n ¼ 32,376) p Value†
Spontaneous MI*
(n ¼ 991)
No Spontaneous MI
(n ¼ 31,915) p Value‡
Demographics
Age, yrs 64.0  11.5 70.1  10.7 63.9  11.5 <0.001 67.4  11.5 63.9  11.5 <0.001
Sex
Female 9,843 (29.9) 206 (38.9) 9,637 (29.8) <0.001 366 (36.9) 9,477 (29.7) <0.001
Race
White 24,922 (75.7) 417 (78.7) 24,505 (75.7) <0.05 735 (74.2) 24,187 (75.8) <0.05
African American 1,847 (5.6) 27 (5.1) 1,820 (5.6) 77 (7.8) 1,770 (5.5)
Asian/Paciﬁc Islander 3,090 (9.4) 55 (10.4) 3,035 (9.4) 92 (9.3) 2,998 (9.4)
All others 3,047 (9.3) 31 (5.8) 3,016 (9.3) 87 (8.8) 2,960 (9.3)
Hispanic ethnicity 3,954 (12.0) 70 (13.2) 3,884 (12.0) 0.40 141 (14.2) 3,813 (11.9) <0.05
Comorbidities
Smoker 10,656 (32.4) 203 (38.3) 10,453 (32.3) <0.01 331 (33.4) 10,325 (32.4) 0.49
Cardiovascular history and risk factors
Acute myocardial infarction 14,957 (45.5) 257 (48.5) 14,700 (45.4) 0.16 546 (55.1) 14,411 (45.2) <0.001
Unstable angina 7,570 (23.0) 111 (32.2) 6,804 (30.8) 0.60 285 (28.8) 7,285 (22.8) <0.001
Hospitalized ischemic stroke or
transient ischemic attack
785 (2.4) 20 (3.8) 765 (2.4) <0.05 29 (2.9) 756 (2.4) 0.26
Peripheral arterial disease 938 (2.9) 31 (5.8) 907 (2.8) <0.001 62 (6.3) 876 (2.7) <0.001
Atrial ﬁbrillation or ﬂutter 2,133 (6.5) 95 (17.9) 2,038 (6.3) <0.001 96 (9.7) 2,037 (6.4) <0.001
Heart failure 1,847 (5.6) 70 (13.2) 1,777 (5.5) <0.001 125 (12.6) 1,722 (5.4) <0.001
Diabetes mellitus 8,773 (26.7) 180 (34.0) 8,593 (26.5) <0.001 422 (42.6) 8,351 (26.2) <0.001
Hypertension 16,754 (50.9) 367 (69.2) 16,387 (50.6) <0.001 640 (64.6) 16,114 (50.5) <0.001
Dyslipidemia 25,529 (77.6) 426 (80.4) 25,103 (77.5) 0.12 806 (81.3) 24,723 (77.5) <0.01
Other medical history
Chronic lung disease 5,601 (17.0) 137 (25.8) 5.464 (16.9) <0.001 217 (21.9) 5,384 (16.9) <0.001
Depression 2,883 (8.8) 64 (12.1) 2,819 (8.7) <0.01 99 (10.0) 2,784 (8.7) 0.16
Systemic cancer 2,735 (8.3) 89 (16.8) 2.646 (8.2) <0.001 116 (11.7) 2,619 (8.2) <0.001
Previous history of hospitalized bleed 471 (1.4) 42 (7.9) 429 (1.3) <0.001 23 (2.3) 448 (1.4) <0.05
Continued on the next page
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1414discharge. Patients who experienced a bleed were
older, more likely to be women, and had a greater
comorbidity burden than patients who did not have a
bleed (Table 1). They were also more likely to receive
warfarin, but antiplatelet therapy use was similar in
the 2 groups. The majority (77%) of spontaneous
bleeds during follow-up were gastrointestinal
(Table 2) and 15% were intracranial, of which one-
third were secondary to trauma.
During follow-up, 991 patients were hospitalized
for an MI (crude rate: 4.26 per 100 person-years; 95%
CI: 4.03 to 4.50), which occurred a median of 127 (IQR:
64 to 222) days post-discharge. Patients who had an
MI during follow-up were older, more likely to be
women, and had a greater comorbidity burden
compared with patients who did not have an MI
(Table 1). Patients who had an MI during follow-up
had lower estimated glomerular ﬁltration rates and
hemoglobin levels at baseline, and received more
medications during follow-up.
There were 4,048 deaths during follow-up. Among
the 530 patients who had a spontaneous bleed, 164(31%) died during follow-up, at a median of 424 (IQR:
66 to 1,276) days after the bleed. Among the 991 pa-
tients who had a spontaneous MI, 315 (32%) died
during follow-up, at a median of 572 (IQR: 75 to 1,504)
days after the MI. Twenty-one deaths occurred
among 39 patients who had both an MI and a bleed.
The crude annual death rate among patients who had
a spontaneous bleed (9.4 per 100 person years) and
patients who had a spontaneous MI (7.6 per 100 per-
son years) was higher than among patients with
neither event (2.6 per 100 person years; Table 3).
After adjustment for demographic characteristics,
comorbid conditions, procedural events, longitudinal
laboratory results, and medication use, spontaneous
bleeding was associated with increased mortality
(adjusted hazard ratio [HR]: 1.61; 95% CI: 1.30 to 2.00)
compared with the reference group of patients
who experienced neither event during follow-up
(Figure 2). The higher adjusted relative rate of death
associated with spontaneous bleeding was similar to
that observed for a spontaneous MI (HR 1.91; 95% CI:
1.62 to 2.25; Figure 2). The results were similar when
TABLE 1 Continued
Entire Cohort
(N ¼ 32,906)
By Bleeding Status By MI Status
Spontaneous Bleed*
(n ¼ 530)
No Spontaneous Bleed
(n ¼ 32,376) p Value†
Spontaneous MI*
(n ¼ 991)
No Spontaneous MI
(n ¼ 31,915) p Value‡
Baseline medication use, 120 days prior to or on
index date§
Angiotensin-converting enzyme inhibitor 9,457 (28.7) 209 (39.4) 9,248 (28.6) <0.001 388 (39.2) 9,069 (28.4) <0.001
Angiotensin II receptor blocker 1,913 (5.8) 42 (7.9) 1,871 (5.8) <0.05 77 (7.8) 1,836 (5.8) <0.01
Diuretic 9,430 (28.7) 227 (42.8) 9,203 (28.4) <0.001 376 (37.9) 9,054 (28.4) <0.001
Beta-blocker 14,039 (42.7) 259 (48.9) 13,780 (42.6) <0.01 525 (53.0) 13,514 (42.3) <0.001
Aldosterone receptor antagonist 345 (1.0) 14 (2.6) 331 (1.0) <0.001 16 (1.6) 329 (1.0) 0.08
Nitrates 6,293 (19.1) 133 (25.1) 6,160 (19.0) <0.001 301 (30.4) 5,992 (18.8) <0.001
Digoxin 1,181 (3.6) 47 (8.9) 1,134 (3.5) <0.001 61 (6.2) 1,120 (3.5) <0.001
Calcium-channel blocker 6,657 (20.2) 155 (29.2) 6,502 (20.1) <0.001 294 (29.7) 6,363 (19.9) <0.001
Statins 12,973 (39.4) 253 (47.7) 12,720 (39.3) <0.001 474 (47.8) 12,499 (39.2) <0.001
Other lipid-lowering agent 1,545 (4.7) 26 (4.9) 1,519 (4.7) 0.82 44 (4.4) 1,501 (4.7) 0.70
Anti-inﬂammatory drugs 5,900 (17.9) 89 (16.8) 5,811 (17.9) 0.49 171 (17.3) 5,729 (18.0) 0.57
Antiplatelet agents
Other antiplatelet agents 1,512 (4.6) 33 (6.2) 1,479 (4.6) 0.07 75 (7.6) 1,437 (4.5) <0.001
Warfarin 1,361 (4.1) 69 (13.0) 1,292 (4.0) <0.001 67 (6.8) 1,294 (4.1) <0.001
Diabetes medications 6,601 (20.1) 131 (24.7) 6,470 (20.0) <0.01 350 (35.3) 6,251 (19.6) <0.001
Baseline laboratory values
Hemoglobin, g/dl
$13.0 17,297 (52.6) 257 (48.5) 17,040 (52.6) <0.001 457 (46.1) 16,840 (52.8) <0.001
10.0–12.9 5,130 (15.6) 159 (30.0) 4,971 (15.4) 264 (26.6) 4,866 (15.3)
<10.0 323 (1.0) 13 (2.5) 310 (0.9) 26 (2.6) 297 (0.9)
Unknown 10,156 (30.9) 101 (19.1) 10,055 (31.1) 244 (24.6) 9,912 (31.1)
Estimated glomerular ﬁltration rate, ml/min/1.73 m2
$60 15,216 (46.2) 198 (37.4) 15,018 (46.4) <0.001 366 (36.9) 14,850 (46.5) <0.001
45–59 5,557 (16.9) 123 (23.2) 5,434 (16.8) 218 (22.0) 5,339 (16.7)
<45, not on dialysis 3,114 (9.5) 110 (20.8) 3004 (9.3) 177 (17.9) 2,937 (9.2)
On dialysis 321 (1.0) 15 (2.8) 306 (0.9) 40 (4.0) 281 (0.9)
Unknown 8,698 (26.4) 84 (15.8) 8,614 (26.6) 190 (19.2) 8,508 (26.7)
Values are mean  SD or n (%). *Spontaneous bleeds or myocardial infarctions (MIs) were deﬁned as bleeds or MIs requiring hospitalization between days 7 and 365 after discharge from the index
hospitalization for percutaneous coronary intervention. †Comparison between patients who had a spontaneous bleed and those who did not. ‡Comparison between patients who had a spontaneous MI and
those who did not. §This refers to drug use prior to the index procedure. Longitudinal medication use after the index procedure was incorporated into the model as a time-updated covariate.
TABLE 2 Site of Spontaneous Bleeding and Case Fatality
Site of Bleeding
Nonfatal
(n ¼ 505)
Fatal
(n ¼ 25)
Total
(n ¼ 530)
Gastrointestinal bleeding 403 (79.8) 6 (24.0) 409 (77.2)
Intracranial bleeding 63 (12.5) 18 (72.0) 81 (15.3)
Traumatic 24 (4.8) 1 (4.0) 25 (4.7)
Nontraumatic 39 (7.7) 17 (68.0) 56 (10.6)
Bleeding at other sites 39 (7.7) 1 (4.0) 40 (7.5)
Values are n (%).
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1415stratiﬁed by indication for the index PCI (elective vs.
urgent). Time-updated adjustment for the use of an-
tiplatelet agents did not change the associations of
spontaneous bleeding (HR: 1.61; 95% CI: 1.30 to 2.01)
or spontaneous MI (HR: 1.92; 95% CI: 1.63 to 2.27) with
all-cause death.
DISCUSSION
In this large, diverse, community-based sample of
adults, spontaneous bleeding episodes between days
7 and 365 after discharge for a PCI were associated
with a 61% higher rate of all-cause mortality during
follow-up. The higher death rate associated with
bleeding was similar to the 91% increase in the rela-
tive death rate associated with experiencing an MI
during follow-up. The higher mortality after a spon-
taneous bleed was not explained by the subsequent
lower use of antiplatelet agents.Several investigators found that periprocedural
major bleeds (either during the index hospitaliza-
tion or within the ﬁrst 30 days after a PCI) are
associated with increased mortality in both “real-
world” populations (1,3,4,7) and randomized trial
cohorts (8–13). Periprocedural bleeding in these
studies was associated with signiﬁcantly increased
TABLE 3 Spontaneous Events and Unadjusted Long-Term Mortality
Number of
Patients
Number of
Deaths
Crude Annual
Mortality Rate
(per 100
Person-Years)
95% Conﬁdence
Interval
Spontaneous bleed during follow-up 530 164 9.4 8.1–10.9
Spontaneous MI during follow-up 991 315 7.6 6.8–8.5
Neither event during follow-up 31,424 3,590 2.6 2.5–2.7
MI ¼ myocardial infarction.
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1416in-hospital, 30-day, and 1-year mortality, similar to
that associated with a periprocedural MI. For
instance, 57,246 periprocedural bleeds among
3,386,688 procedures in the American College of
Cardiology National Cardiovascular Data Registry
CathPCI Registry in the United States between 2004
and 2011 were associated with higher in-hospital
death across all strata of pre-procedural bleeding
risk (4). The authors estimated that 12% of the
adjusted population-attributable risk for in-hospitalFIGURE 2 Increased Risk of Death After Spontaneous Bleeding or M
0.1
Event
Adjusted Haz
(95% Confiden
Among elective PCIs (n = 28,391): 
1.66 (1.30Spontaneous Bleed
Spontaneous MI 2.00 (1.68
Among urgent and emergent PCIs (n = 4,515): 
1.49 (0.90Spontaneous Bleed
Spontaneous MI 1.89 (1.29
Among all PCIs (n = 32,906): 
1.61 (1.30-Spontaneous Bleed
Spontaneous MI 1.91 (1.62
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receptor blockers, diuretics, beta-blockers, anti-inﬂammatory agents, ni
medications), and time-varying estimated glomerular ﬁltration rate. Abbdeath was related to major bleeding. Similarly, an
analysis of 5,384 patients from 4 randomized
controlled trials of abciximab noted that major
hemorrhage in the ﬁrst 30 days post-procedure was
associated with a similar death risk at 1 year as a
periprocedural MI (9).
Our study extends these observations to non-
procedural bleeding after hospital discharge from the
index PCI. We found that spontaneous, late bleeding
was signiﬁcantly associated with higher mortality,
comparable to the adverse effect of a late, sponta-
neous MI. Of note, our cohort enrolled a broad
spectrum of patients undergoing PCI within typical
clinical care, including low-risk patients under-
going elective procedures, and high-risk patients
undergoing urgent or emergent revascularization
for acute coronary syndrome. Stratiﬁcation by
whether the procedure was elective or urgent did
not materially change the results. Finally, this
study included a large, community-based patient
cohort; thus, our ﬁndings likely reﬂect “real-world”
outcomes.I After PCI
Lower risk of death Higher risk of death
1 10
ard Ratio 
ce Interval)
-2.11)
-2.37)
-2.48)
-2.79)
2.00)
-2.25)
nts having a spontaneous bleed or MI from days 7 to 365 after
omprised of patients who experienced neither event during follow-up.
r bleed prior to index date, MI or bleed during index hospitalization or
pertension, diabetes, dyslipidemia, unstable angina, mitral or aortic
ation, heart failure, peripheral arterial disease, dementia, chronic lung
medications (angiotensin-converting enzyme inhibitors, angiotensin
trates, digoxin, calcium-channel blockers, statins, and diabetes
reviations as in Figure 1.
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1417There are 2 plausible explanations for the associa-
tion between bleeding and mortality: 1) a major bleed
directly increases long-term mortality; or 2) a major
bleed is a marker of overall poor prognosis (i.e., the
sickest patients are at a higher risk for both bleeding
and death). These alternative hypotheses cannot be
tested in a randomized trial, so we must rely on
experimental and observational data to provide key
insights. Substantial theoretical, basic, and clinical
evidence suggests a causal relationship between
bleeding after PCI and subsequent mortality (Central
Illustration). Bleeding produces a prothrombotic
milieu by activating the coagulation cascade and
up-regulating cytokines such as plasminogen acti-
vator inhibitor-1. Large bleeds produce hypovolemia
and anemia, which reduce oxygen delivery and cause
reﬂex tachycardia, which increase oxygen demand
and can lead to myocardial ischemia in patients
with obstructive coronary disease (30). BloodCENTRAL ILLUSTRATION Spontaneous Bleed Versus MI A
Potential
     •  Arrh
     •  Card
     •  Hea
Spontaneous Bleed
Increased Mortality
Potential Mechanisms:
     •  Activation of coagulation cascade
     •  Increased prothrombotic cytokines
     •  Hypovolemia
     •  Anemia (compromised 
         oxygen delivery)
     •  Reflex tachycardia (increased 
         myocardial oxygen demand)
     •  Transfusion of blood products
     •  Cessation of antiplatelet 
         and anticoagulant therapy
Kazi, D.S. et al. J Am Coll Cardiol. 2015; 65(14):1411–20. 
Patients surviving the index percutaneous coronary intervention (PCI) ma
ﬁrst year post-discharge, which may result in increased long-term morttransfusions produce secondary biochemical changes
that adversely impact microcirculatory ﬂow, hypoxia-
induced vasodilation, oxygen delivery (31,32), and
survival (33,34). Some of these adverse effects are
accentuated in the setting of endothelial dysfunction,
making ischemic myocardium particularly vulner-
able. Additionally, the development of anemia may
also adversely affect long-term clinical outcomes due
to increased neurohormonal activation and ventric-
ular remodeling, which result in greater wall stress
and increased oxygen consumption (35–37). However,
randomized studies of interventions that reduce
periprocedural bleeding (e.g., a transradial approach
for access or use of bivalirudin) have produced mixed
results, with some demonstrating reduced short-term
and long-term risk of death (38,39), and others
showing no effect (40–42).
Our ﬁndings, particularly if reproduced in other co-
horts and in the setting of the newer antiplatelet agents,fter PCI: Potential Pathogenetic Mechanisms
Index PCI
Survival to Discharge
 Mechanisms:
ythmias
iogenic shock
rt failure
Spontaneous MI Neither Event
Increased Mortality Comparator
y experience a spontaneous bleed or myocardial infarction (MI) in the
ality compared with patients experiencing neither event.
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for systematic evaluation of bleeding avoidance strate-
gies after hospital discharge (34,43,44). Although gastric
acid suppression with proton pump inhibitors or
histamine-2 receptor antagonists signiﬁcantly reduces
the risk of bleeding in patients on antiplatelet therapy, no
randomized trials have compared the 2 groups of agents
in patients on dual antiplatelet therapy (45). Observa-
tional data suggest that proton pump inhibitors offer
greater protection from upper gastrointestinal bleeding
than histamine-2 receptor antagonists in this setting
(46), but whether these agents also improve long-term
thrombotic outcomes should be explored. Secondly,
because the reduced incidence of MI and stent throm-
bosis comes at the expense of an increased risk
of bleeding (47–49), the net clinical beneﬁt of long-term
use of potent antiplatelet and antithrombotic drugs af-
ter PCI should be re-examined. Validated tools to predict
the risk of bleeding andMI after PCI may help physicians
personalize treatment plans for patients on the basis of
relative risk for bleeding and thrombotic events.
Although routine use of risk prediction tools has been
challenging, the rapid expansion of electronic health re-
cords nationally may facilitate integration of effective
clinical decision support systems within the clinical
workﬂow. Third, our ﬁndings argue that comparative
effectiveness studies of coronary revascularization
should focus on both harms and beneﬁts (9). Although
studies of long-term outcomes of PCI have traditionally
targeted recurrent MI, the similar prognostic impact of
thrombotic and bleeding events on long-term mortality
suggests that bleeding should also be considered when
determining the net clinical beneﬁt of treatment. This is
an especially important consideration because major
bleeds outnumbered MIs in the intervention arms of
pivotal trials leading to the approval of both ticagrelor
and prasugrel (50,51).
STUDY LIMITATIONS. We did not have data on
selected variables (e.g., coronary anatomy or left
ventricular systolic function) that may have inﬂu-
enced long-term outcomes in this cohort. We could
not systematically capture data on minor bleeds that
did not lead to hospitalization, asymptomatic MIs,
and MIs resulting in sudden cardiac death prior to
hospitalization. The low observed rate of concurrent
bleeding and MI in our dataset may result from
the speciﬁcity of the algorithm used to identify these
events in claims data. We could not grade the severity
of bleeding from the available data. However, we
adjusted for longitudinal data on a wide range
of comorbidities, drug therapies, and laboratory
values—many of which were not accounted for in
prior studies—in a large community-based sample ofpatients, enabling us to mitigate the impact of major
known confounders. Although the observed associa-
tion between bleeding and death persisted after
extensive adjustment for baseline and longitudinal
confounding variables, we cannot completely rule out
the effects of unmeasured or residual confounding.
This analysis includes patients undergoing PCI
from 1996 through 2008, during which PCI evolved
considerably. However, given the rarity of the events
studied, further stratiﬁcation (e.g., by stent type)
would have resulted in an unacceptable loss of
statistical power. Given that this study examines the
impact of spontaneous bleeding or MI occurring
several months post-discharge, this association is
unlikely to be modiﬁed by technical details of the
procedure. Nevertheless, this question needs to be
examined in a more contemporary cohort, particu-
larly in the context of newer antiplatelet and novel
anticoagulant agents unavailable during the study
period to determine whether the observed safety-
effectiveness tradeoffs extend to patients receiving
these agents. Finally, we did not have access to car-
diovascular versus noncardiovascular causes of
death, which might be instructive because MI and
bleeding may be associated with all-cause death
through different mechanisms. Future studies should
examine the association of spontaneous bleeding and
MI after PCI with cause-speciﬁc mortality.
CONCLUSIONS
Among a large, diverse cohort of patients receiving
PCI, spontaneous bleeding after discharge was
independently associated with signiﬁcantly higher
long-term mortality during follow-up, comparable
to that of an MI. This argues for systematic evalu-
ation of strategies to reduce bleeding beyond the
index procedure, and emphasizes the need for
careful long-term evaluation of the net clinical
beneﬁt of emerging antiplatelet and antithrombotic
strategies in the management of coronary heart
disease.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Post-
procedural bleeding and myocardial infarction in patients
undergoing PCI are associated with increased mortality 1
year later.
TRANSLATIONAL OUTLOOK: Additional studies are
needed to inform decisions about the intensity and
duration of antiplatelet therapy on the basis of individu-
alized assessments of the risks of thrombotic and
bleeding events for patients undergoing PCI.
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